InvestSMART

Pacific Edge Limited (ASX:PEB)

ALERT: Price-sensitive ASX Announcement for PEB
Current share price for PEB : $0.250 0.05 (25%)+
Announcement
Release
23 Feb 2026 9:21AM
Price at Release
$0.200
Full Release
download
Summary
Pacific Edge Limited announced that an expert panel expressed strong support for the use of urine-based biomarkers in the evaluation of hematuria, asserting these tests as medically necessary and suitable for Medicare coverage. The panel's endorsement was based on substantial evidence, including studies like STRATA and the Kaiser Study, which demonstrated the clinical utility of Cxbladder Triage and Triage Plus tests. These tests were highlighted for their potential to improve patient outcomes, especially in rural areas lacking urological care, facilitate early bladder cancer detection, and offer a non-invasive alternative to cystoscopy. The panel urged Medicare to cover these biomarkers, citing their benefits in ruling out bladder cancer and reducing unnecessary referrals. Pacific Edge anticipates a draft Medicare coverage policy within approximately six months, following which a final coverage decision may be made within an additional six months.
Key Points
  • Expert panel supports urine-based biomarkers for hematuria evaluation.
  • Tests seen as medically necessary and appropriate for Medicare coverage.
  • Evidence cited includes STRATA and Kaiser Study.
  • Cxbladder tests improve outcomes, especially in rural areas.
  • Tests facilitate early detection and offer non-invasive alternatives.
  • Panel urges Medicare coverage for these tests.
  • Draft Medicare policy anticipated within six months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.